Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Open access
Home, Philip D, Pocock, Stuart J, Beck-Nielsen, Henning, Curtis, Paula S, Gomis, Ramon, Hanefeld, Markolf, Jones, Nigel P, Komajda, Michel, McMurray, John JV·2009·The Lancet

Abstract

Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety.Methods In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1.20. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00379769.Findings 321 people in the rosiglitazone group and 323 in the active control group experienced the primary outcome during a mean 5.5-year follow-up, meeting the criterion of non-inferiority (HR 0.99, 95% CI 0.85-1.16). HR was 0.84 (0.59-1.18) for cardiovascular death, 1.14 (0.80-1.63) for myocardial infarction, and 0.72 (0.49-1.06) for stroke. Heart failure causing admission to hospital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2.10, 1.35-3.27, risk difference per 1000 person-years 2.6, 1.1-4.1). Upper and distal lower limb fracture rates were increased mainly in women randomly assigned to rosiglitazone. Mean HbA(1c) was lower in the rosiglitazone group than in the control group at 5 years.Interpretation Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.Funding GlaxoSmithKline plc, UK.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)60953-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 1,393

Metadata

Authors
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J.
Affiliations
  • Newcastle University (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • University of Glasgow (GB)
Corresponding author
Home, Philip D
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-06
Volume
373
Issue
9681
Pages
2125-2135
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2131490500
Cited by
1,393
References
23
Citations by year
2026: 15 · 2025: 29 · 2024: 43 · 2023: 38 · 2022: 41 · 2021: 49 · 2020: 79 · 2019: 73 · 2018: 106 · 2017: 85 · 2016: 91 · 2015: 81 · 2014: 97 · 2013: 89 · 2012: 106
FWCI
114.05
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
rosiglitazone, type 2 diabetes, metformin, sulfonylureas, cardiovascular outcomes, cardiovascular hospitalization, cardiovascular mortality, myocardial infarction, stroke, heart failure, fracture risk, non-inferiority, HbA1c, drug safety, older adults
MeSH terms
Rosiglitazone, Administration, Oral, Angina, Unstable, Body Weight, Diabetes Mellitus, Type 2, Diuretics, Drug Therapy, Combination, Drug Utilization, Female, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Cholesterol, HDL, Cholesterol, LDL, Male, Metformin, Middle Aged, Myocardial Infarction, Neoplasms, Prospective Studies, Sex Factors, Sulfonylurea Compounds, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Thiazolidinediones, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60953-3
The paper
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet. https://doi.org/10.1016/s0140-6736(09)60953-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.